Rolvedon sales for the 4th quarter of $10 million exceeds average analyst estimates by 2.5 times with the high estimate being a bit over $5 million and the low at $1.5 million. Also that is almost 2 times the estimate for the 1st quarter 2023. This is a great start. If they can follow through on this, 2023 may be a good year for SPPI's PPS.
So the costs have also collapsed? Cash, cash equivalents and marketable securities of $75 million at 12/31/2022, which is expected to extend cash runway through 2024
News 
Market Data 
Discover 
